The Medicines and Healthcare Products Regulatory Agency (MHRA) has proposed a comprehensive overhaul of medical regulations to address the rapid integration of artificial intelligence into the National Health Service. The agency, which oversees medical devices and drug licensing, released 44 recommendations following an independent commission that gathered feedback from over 12,000 clinicians and patients.
MHRA official Lawrence Tallon noted that existing regulatory frameworks were designed for traditional medical hardware, such as stethoscopes or joint replacements, rather than software that evolves over time. Unlike static medical devices, AI models can adapt and change as they ingest new data, necessitating a more dynamic approach to oversight. Tallon emphasized that the goal is to ensure patients maintain confidence in the healthcare system as AI becomes a routine component of clinical delivery.
The proposed changes include a continuous monitoring system that would allow the MHRA to revoke approval for tools that lose effectiveness or malfunction. The agency also suggests implementing an "L plate" system to facilitate the supervised trial of new models and granting regulators the authority to penalize developers who fail to meet safety standards. Furthermore, the report advocates for patient transparency, ensuring individuals are informed when AI is utilized in their care.
The integration of AI, particularly in administrative roles like medical scribing, has already begun; reports indicate that approximately 40% of UK GPs currently use AI-powered tools to record consultations. However, the transition has raised concerns regarding patient privacy and the potential for bias in training data. While some experts, such as ophthalmologist Professor Alastair Denniston, view AI as a transformative advancement comparable to the discovery of antibiotics, others highlight the need for human oversight to correct errors and respect patient preferences regarding the use of automated technology.
Source: BBC News
No comments yet. Be the first to share your thoughts.